Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis - PubMed (original) (raw)
. 2010 Jun;16(6):1040-50.
doi: 10.1002/ibd.21167.
Affiliations
- PMID: 19924805
- DOI: 10.1002/ibd.21167
Targeting TGF-beta1 by employing a vaccine ameliorates fibrosis in a mouse model of chronic colitis
Yanbing Ma et al. Inflamm Bowel Dis. 2010 Jun.
Abstract
Background: Intestinal fibrosis and stricture formation are major complications of inflammatory bowel disease (IBD), for which there are currently few effective treatments. We sought to investigate whether targeting transforming growth factor-beta1 (TGF-beta1), a key profibrotic mediator, with a peptide-based virus-like particle vaccine would be effective in suppressing intestinal fibrosis by using a mouse model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced chronic colitis.
Methods: The vaccine was prepared by inserting a peptide derived from mouse TGF-beta1 into a carrier hepatitis B core antigen using gene recombination methods. Chronic colitis was induced in BALB/c mice by 8 weekly TNBS administrations. Mice were subcutaneously injected with vaccine, carrier, or phosphate-buffered saline (PBS) in 2 separate studies: either before or after acute inflammatory responses commenced.
Results: Sera from vaccinated mice exhibited significantly elevated levels of TGF-beta1-specific immunoglobulin G (IgG), which inhibited TGF-beta1-induced luciferase production in mink lung epithelial cells. In the chronic colitis model, mice receiving vaccine showed improved body weight gain and significantly reduced colonic collagen deposition. Hematoxylin and eosin staining and semiquantitative scoring indicated that vaccination even ameliorated colonic inflammation. Cytokine profile analysis revealed that levels of TGF-beta1, interleukin (IL)-17, and IL-23 in vaccinated mouse colon tissues were decreased, and that percentages of IL-17-expressing CD4(+) lymphocytes in mesenteric lymph node cells were reduced. Furthermore, Smad3 phosphorylation, a key event in TGF-beta signaling, was decreased in colonic tissue in vaccinated mice.
Conclusions: This TGF-beta1 peptide-based vaccine, which suppressed excessive TGF-beta1 bioactivity, may prevent the development of intestinal fibrosis and associated complications, presenting a novel approach in the treatment of IBD.
Similar articles
- Targeting IL-12/IL-23 by employing a p40 peptide-based vaccine ameliorates TNBS-induced acute and chronic murine colitis.
Guan Q, Ma Y, Hillman CL, Qing G, Ma AG, Weiss CR, Zhou G, Bai A, Warrington RJ, Bernstein CN, Peng Z. Guan Q, et al. Mol Med. 2011;17(7-8):646-56. doi: 10.2119/molmed.2010.00252. Epub 2011 Mar 11. Mol Med. 2011. PMID: 21424108 Free PMC article. - Employing an IL-23 p19 vaccine to block IL-23 ameliorates chronic murine colitis.
Guan Q, Burtnick HA, Qing G, Weiss CR, Ma AG, Ma Y, Warrington RJ, Peng Z. Guan Q, et al. Immunotherapy. 2013 Dec;5(12):1313-22. doi: 10.2217/imt.13.141. Immunotherapy. 2013. PMID: 24283842 - An IL-17 peptide-based and virus-like particle vaccine enhances the bioactivity of IL-17 in vitro and in vivo.
Guan Q, Weiss CR, Qing G, Ma Y, Peng Z. Guan Q, et al. Immunotherapy. 2012 Dec;4(12):1799-807. doi: 10.2217/imt.12.129. Immunotherapy. 2012. PMID: 23240747 - Cytokines mediating the induction of chronic colitis and colitis-associated fibrosis.
Fichtner-Feigl S, Strober W, Geissler EK, Schlitt HJ. Fichtner-Feigl S, et al. Mucosal Immunol. 2008 Nov;1 Suppl 1(0 1):S24-7. doi: 10.1038/mi.2008.41. Mucosal Immunol. 2008. PMID: 19079223 Free PMC article. Review. - Smad7 as a positive regulator of intestinal inflammatory diseases.
Monteleone G, Laudisi F, Stolfi C. Monteleone G, et al. Curr Res Immunol. 2023 Jan 24;4:100055. doi: 10.1016/j.crimmu.2023.100055. eCollection 2023. Curr Res Immunol. 2023. PMID: 36714553 Free PMC article. Review.
Cited by
- Inflammation accelerating intestinal fibrosis: from mechanism to clinic.
Xin S, Liu X, He C, Gao H, Wang B, Hua R, Gao L, Shang H, Sun F, Xu J. Xin S, et al. Eur J Med Res. 2024 Jun 18;29(1):335. doi: 10.1186/s40001-024-01932-2. Eur J Med Res. 2024. PMID: 38890719 Free PMC article. Review. - Fibrosis in IBD: from pathogenesis to therapeutic targets.
Rieder F, Mukherjee PK, Massey WJ, Wang Y, Fiocchi C. Rieder F, et al. Gut. 2024 Apr 5;73(5):854-866. doi: 10.1136/gutjnl-2023-329963. Gut. 2024. PMID: 38233198 Review. - Engaging natural antibody responses for the treatment of inflammatory bowel disease via phosphorylcholine-presenting nanofibres.
Curvino EJ, Roe EF, Freire Haddad H, Anderson AR, Woodruff ME, Votaw NL, Segura T, Hale LP, Collier JH. Curvino EJ, et al. Nat Biomed Eng. 2024 May;8(5):628-649. doi: 10.1038/s41551-023-01139-6. Epub 2023 Nov 27. Nat Biomed Eng. 2024. PMID: 38012308 Free PMC article. - Vaccination therapy for inflammatory bowel disease.
Liu Y, Liao F. Liu Y, et al. Hum Vaccin Immunother. 2023 Aug;19(2):2259418. doi: 10.1080/21645515.2023.2259418. Epub 2023 Sep 29. Hum Vaccin Immunother. 2023. PMID: 37771317 Free PMC article. Review. - Molecular Basis of Intestinal Fibrosis in Inflammatory Bowel Disease.
Andoh A, Nishida A. Andoh A, et al. Inflamm Intest Dis. 2022 Dec 1;7(3-4):119-127. doi: 10.1159/000528312. eCollection 2023 Mar. Inflamm Intest Dis. 2022. PMID: 37064539 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials